AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7515706 — intervention group
Group type: COMPARATOR
Intervention: No magnesium (control group)
Number of subjects: 140
Study 3070047 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent health education and skill intervention
Number of subjects: 387
Study 3070047 — intervention group
Group type: COMPARATOR
Intervention: Monetary incentive for quitting
Number of subjects: 387
Study 31318225 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized assessment and treatment program (IATP)
Number of subjects: 198
Study 31318225 — intervention group
Group type: EXPERIMENTAL
Intervention: IATP with contingency management (IATP-CM)
Number of subjects: 198
Study 31318225 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement cognitive-behavioral treatment (MET-CBT)
Number of subjects: 198
Study 31318225 — intervention group
Group type: COMPARATOR
Intervention: MET-CBT with contingency management (MET-CBT-CM)
Number of subjects: 198
Study 31318225 — intervention group
Group type: EXPERIMENTAL
Intervention: IATP
Number of subjects: 198
Study 29921409 — intervention group
Group type: EXPERIMENTAL
Intervention: New flowable resin‐based composite
Number of subjects: 28
Study 29921409 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid composite
Number of subjects: 28
Study 29921409 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal contact
Number of subjects: 28
Study 27552564 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-epicatechin (EPI) at a total daily dose of 100mg
Number of subjects: 0
Study 27552564 — intervention group
Group type: COMPARATOR
Intervention: (+)-catechin
Number of subjects: 0
Study 25571981 — intervention group
Group type: EXPERIMENTAL
Intervention: sTAP block with 0.25% bupivacaine
Number of subjects: 54
Study 25571981 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (LA) infiltration with 0.25% bupivacaine
Number of subjects: 54
Study 25571981 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 54
Study 23452830 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to medical care
Number of subjects: 1890
Study 23452830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic conditions
Number of subjects: 1890
Study 23452830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 1890
Study 23452830 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 1890
Study 20590504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine plus vaginal misoprostol (Group I)
Number of subjects: 49
Study 20590504 — intervention group
Group type: COMPARATOR
Intervention: Only vaginal misoprostol (Group II)
Number of subjects: 49
Study 18361183 — intervention group
Group type: COMPARATOR
Intervention: Gender-specific cognitive-behavioral stress management training (6 sessions)
Number of subjects: 80
Study 16983741 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (25 Gy in five fractions of 5 Gy)
Number of subjects: 312
Study 16983741 — intervention group
Group type: COMPARATOR
Intervention: Preoperative conventionally fractionated chemoradiation (50.4 Gy in 28 fractions of 1.8 Gy, bolus 5-fluorouracil and leucovorin)
Number of subjects: 312
Study 16983741 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy
Number of subjects: 312
Study 16983741 — intervention group
Group type: COMPARATOR
Intervention: Preoperative conventionally fractionated chemoradiation
Number of subjects: 312
Study 14524058 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based guidelines implemented in Südwürttemberg after 6 months.
Number of subjects: 400
Study 14524058 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (Südbaden) without the new guidelines.
Number of subjects: 400
Study 14524058 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatments (various types).
Number of subjects: 400
Study 10937402 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hazard reduction program
Number of subjects: 530
Study 8929605 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade
Number of subjects: 11
Study 8929605 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 1569294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone (met‐GH) infusion (160 ng/kg/min lasting 180 min)
Number of subjects: 6
Study 1569294 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox sustained release (ACX-SR) administered at 21:30 h and 09:30 h
Number of subjects: 6
Study 1569294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2866257 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg t.i.d. on day 1, 10 mg b.i.d. on day 2, 10 mg o.d. for the remainder of the study)
Number of subjects: 65
Study 2866257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 2866257 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 65
Study 31634003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyaluronic Acid (HA) 1 week before the marathon
Number of subjects: 20
Study 31634003 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS) control
Number of subjects: 20
Study 30680396 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF) combined with Bio‐oss
Number of subjects: 30
Study 30680396 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery
Number of subjects: 30
Study 26829000 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 35
Study 26829000 — intervention group
Group type: COMPARATOR
Intervention: Sedentary attention control program
Number of subjects: 35
Study 24828079 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (antidepressant, selective serotonin reuptake inhibitor)
Number of subjects: 2
Study 24828079 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 2
Study 24828079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 22723318 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6370 (300 mg)
Number of subjects: 12
Study 22723318 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 (80 mg) plus insulin (1 mU/kg · min)
Number of subjects: 12
Study 22723318 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (0.8 mU/kg · min)
Number of subjects: 12
Study 22723318 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (1 mU/kg · min)
Number of subjects: 12
Study 20585110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 534
Study 17253376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 24
Study 17253376 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24
Study 15380907 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 kcal, 20 g protein supplement
Number of subjects: 12
Study 15380907 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 kcal, 3.5 g protein supplement
Number of subjects: 12
Study 15380907 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 12
Study 11472706 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 12 weeks
Number of subjects: 0
Study 11472706 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 3,000 mg daily for 12 weeks
Number of subjects: 0
Study 10399514 — intervention group
Group type: EXPERIMENTAL
Intervention: Softened endotracheal tube (heated in warm water)
Number of subjects: 62
Study 10399514 — intervention group
Group type: COMPARATOR
Intervention: Unsoftened endotracheal tube (intact)
Number of subjects: 62
Study 7851059 — intervention group
Group type: COMPARATOR
Intervention: Complete bed rest for 10 hours after ingestion of the maintenance dose of digoxin
Number of subjects: 10
Study 7851059 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activity
Number of subjects: 10
Study 3132910 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day cathartic/enema preparation with oral administration of erythromycin and neomycin
Number of subjects: 593
Study 3132910 — intervention group
Group type: COMPARATOR
Intervention: Orthograde lavage preparation with oral administration of metronidazole and neomycin
Number of subjects: 593
Study 31473126 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode phototherapy
Number of subjects: 32
Study 31473126 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent tube phototherapy
Number of subjects: 32
Study 29529614 — intervention group
Group type: EXPERIMENTAL
Intervention: preopPTEd (one‐on‐one preoperative physical therapy education session and access to a web‐based microsite)
Number of subjects: 126
Study 29529614 — intervention group
Group type: EXPERIMENTAL
Intervention: preopPTEd
Number of subjects: 126
Study 26493036 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCC (Posterior Continuous Curvilinear Capsulorhexis)
Number of subjects: 20
Study 26493036 — intervention group
Group type: COMPARATOR
Intervention: NCCC (No Continuous Curvilinear Capsulorhexis)
Number of subjects: 20
Study 25642826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dancing program
Number of subjects: 35
Study 25642826 — intervention group
Group type: COMPARATOR
Intervention: Health-related exercise group
Number of subjects: 35
Study 24158878 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 20-100 μg iv
Number of subjects: 120
Study 21918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction at ≤ 13 weeks
Number of subjects: 1090
Study 21918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction at 14-17 weeks
Number of subjects: 1090
Study 21918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction at 18-21 weeks
Number of subjects: 1090
Study 21918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction at ≥ 22 weeks
Number of subjects: 1090
Study 21918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction
Number of subjects: 1090
Study 18520295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetinib (ZD6474) at a dose of up to 300 mg once daily
Number of subjects: 0
Study 18520295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetinib administered concurrently with chemotherapy
Number of subjects: 0
Study 17023869 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 303
Study 12639245 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART supplemented with interleukin 2 (IL-2)
Number of subjects: 0
Study 12639245 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART supplemented with Remune
Number of subjects: 0
Study 12639245 — intervention group
Group type: COMPARATOR
Intervention: Initial HAART
Number of subjects: 0
Study 15808378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal insert (10 mg over 12 h)
Number of subjects: 144
Study 15808378 — intervention group
Group type: COMPARATOR
Intervention: Cervical gel (0.5 mg, twice in 12 h)
Number of subjects: 144
Study 10522767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention using Orem's self‐care theory, five 30‐min sessions once a week during treatment and two follow-up sessions after treatment.
Number of subjects: 67
Study 10522767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nursing intervention).
Number of subjects: 67
Study 8527016 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric ibuprofen
Number of subjects: 0
Study 8527016 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1981020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 1981020 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 15
Study 7017017 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of doxycycline per dose, taken biweekly for three weeks
Number of subjects: 46
Study 7017017 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken biweekly for three weeks
Number of subjects: 46
Study 7017017 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of doxycycline per dose
Number of subjects: 46
Study 7017017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31304892 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed stoma
Number of subjects: 487
Study 31304892 — intervention group
Group type: COMPARATOR
Intervention: No stoma (control)
Number of subjects: 487
Study 31304892 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer survivors (both groups)
Number of subjects: 487
Study 27852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate + Infliximab (M+I) (5 mg/kg)
Number of subjects: 18
Study 27852695 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate + Placebo (M+P)
Number of subjects: 18
Study 27852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy (after 54 weeks)
Number of subjects: 18
Study 26399192 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Aphasia Therapy (CIAT), 4 hours/day for 10 consecutive business days (total 40 hours)
Number of subjects: 24
Study 26399192 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 24
Study 23422107 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH (1-34) 20 µg daily for 18 months
Number of subjects: 453
Study 23422107 — intervention group
Group type: COMPARATOR
Intervention: elcatonin 20 U weekly for 12 months
Number of subjects: 453
Study 21561303 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with ropivacaine, ketorolac, and epinephrine
Number of subjects: 40
Study 21561303 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 40
Study 21561303 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 40
Study 19761938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (cTnI) prototype assay
Number of subjects: 2045
Study 17702701 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-enhanced upper extremity exercises
Number of subjects: 40
Study 14749206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day for 24 weeks)
Number of subjects: 30
Study 14749206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11384826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2h in-office training program and/or self-study workbook
Number of subjects: 282
Study 11384826 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 282
Study 9987640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute AF in dogs (n = 5)
Number of subjects: 17
Study 9987640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lone AF in patients (n = 7)
Number of subjects: 17
Study 9987640 — intervention group
Group type: COMPARATOR
Intervention: Control patients (CTL, n = 10)
Number of subjects: 17
Study 9987640 — intervention group
Group type: EXPERIMENTAL
Intervention: AFDCM patients (n = 5)
Number of subjects: 17
Study 8091041 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatments for rheumatoid arthritis
Number of subjects: 0
Study 8091041 — intervention group
Group type: EXPERIMENTAL
Intervention: Health effects of air pollution
Number of subjects: 0
Study 3041829 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 X 10(6) units of recombinant interferon alpha‐2a per day
Number of subjects: 48
Study 3041829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3041829 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 X 10(6) units of recombinant interferon alpha‐2a per day
Number of subjects: 48
Study 31055579 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative Dance (CD)
Number of subjects: 82
Study 31055579 — intervention group
Group type: COMPARATOR
Intervention: Stretching (ST)
Number of subjects: 82
Study 27878847 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive programme educating on implementation, strategies, goals, project management and leadership
Number of subjects: 8
Study 27878847 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation plan supplementary to the guideline
Number of subjects: 8
Study 25880826 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 0
Study 25880826 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 23778767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific mandibular mobilization (NMM)
Number of subjects: 50
Study 23778767 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 21355716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Regular Human Insulin (RHI)
Number of subjects: 29
Study 21355716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Insulin Lispro (IL)
Number of subjects: 29
Study 21355716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) Insulin Lispro (IL) and Regular Human Insulin (RHI)
Number of subjects: 29
Study 20072737 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants
Number of subjects: 10
Study 20072737 — intervention group
Group type: COMPARATOR
Intervention: Conventional implants
Number of subjects: 10
Study 20690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher instructions alone (E1)
Number of subjects: 0
Study 20690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education alone (E2)
Number of subjects: 0
Study 20690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of teacher instruction and peer education (E3)
Number of subjects: 0
Study 20690287 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 15105040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh apples
Number of subjects: 15
Study 15105040 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed applesauce
Number of subjects: 15
Study 15105040 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 11973101 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5%
Number of subjects: 51
Study 11973101 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 51
Study 9593358 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITBN)
Number of subjects: 503
Study 9593358 — intervention group
Group type: COMPARATOR
Intervention: Control (no ITBN)
Number of subjects: 503
Study 8541750 — intervention group
Group type: EXPERIMENTAL
Intervention: Exciting video
Number of subjects: 12
Study 8541750 — intervention group
Group type: COMPARATOR
Intervention: Pleasant video
Number of subjects: 12
Study 8541750 — intervention group
Group type: COMPARATOR
Intervention: Amusing video
Number of subjects: 12
Study 8541750 — intervention group
Group type: COMPARATOR
Intervention: No video
Number of subjects: 12
Study 2228349 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytically oriented group psychotherapy (STG)
Number of subjects: 79
Study 2228349 — intervention group
Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 79
Study 510179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol, 0.8 ml/kg
Number of subjects: 16
Study 510179 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine, 100 mg
Number of subjects: 16
Study 510179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31501069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream-type adhesive
Number of subjects: 200
Study 31501069 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-type adhesive
Number of subjects: 200
Study 31501069 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 200
Study 31253216 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 114
Study 31253216 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 114
Study 27397024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0
Study 27397024 — intervention group
Group type: COMPARATOR
Intervention: Total laryngectomy
Number of subjects: 0
Study 25735992 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-40411813
Number of subjects: 100
Study 25735992 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg JNJ-40411813
Number of subjects: 100
Study 25735992 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-225 mg JNJ-40411813
Number of subjects: 100
Study 25735992 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg JNJ-40411813
Number of subjects: 100
Study 25735992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24077770 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with immediate performance feedback
Number of subjects: 155
Study 24077770 — intervention group
Group type: COMPARATOR
Intervention: Training with no performance feedback
Number of subjects: 155
Study 22290001 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100
Study 22290001 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100
Study 22290001 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg NTG plus 3 mg/kg 2% lidocaine
Number of subjects: 100
Study 22290001 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg 2% lidocaine diluted with saline (Control Group LS)
Number of subjects: 100
Study 19653788 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Contingencies (MC)
Number of subjects: 120
Study 19653788 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher Contingency (VC)
Number of subjects: 120
Study 19653788 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 120
Study 16409324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous 17% (w/v) ethylenediaminetetraacetic acid rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Number of subjects: 80
Study 16409324 — intervention group
Group type: COMPARATOR
Intervention: Tap water rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Number of subjects: 80